↓ Skip to main content

Low-value approvals and high prices might incentivize ineffective drug development

Overview of attention for article published in Nature Reviews Clinical Oncology, May 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#31 of 2,361)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
3 news outlets
twitter
240 X users
facebook
2 Facebook pages
q&a
1 Q&A thread

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Low-value approvals and high prices might incentivize ineffective drug development
Published in
Nature Reviews Clinical Oncology, May 2018
DOI 10.1038/s41571-018-0030-2
Pubmed ID
Authors

Vinay Prasad, Christopher McCabe, Sham Mailankody

X Demographics

X Demographics

The data shown below were collected from the profiles of 240 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 15%
Student > Ph. D. Student 7 11%
Other 6 10%
Student > Postgraduate 5 8%
Student > Doctoral Student 3 5%
Other 13 21%
Unknown 18 30%
Readers by discipline Count As %
Medicine and Dentistry 15 25%
Biochemistry, Genetics and Molecular Biology 7 11%
Philosophy 3 5%
Agricultural and Biological Sciences 3 5%
Economics, Econometrics and Finance 3 5%
Other 10 16%
Unknown 20 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 174. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2023.
All research outputs
#236,395
of 25,774,185 outputs
Outputs from Nature Reviews Clinical Oncology
#31
of 2,361 outputs
Outputs of similar age
#5,182
of 342,102 outputs
Outputs of similar age from Nature Reviews Clinical Oncology
#3
of 54 outputs
Altmetric has tracked 25,774,185 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,361 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,102 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.